---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Care management intervention strategies"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Care management intervention strategies. Topics: AASM 2019 recommendations for educational, behavioral, troubleshooting, and telemonitoring interventions; VA/DoD 2025 recommendation for in-person or telehealth adherence interventions; VA/DoD 2025 recommendation for a short course of eszopiclone to improve positive airway pressure usage; Behavioral intervention effect on CPAP use across studies; 2 further topics. 6 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/care-management-intervention-strategies"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Care management intervention strategies

<a id="heading-2.2.2.4"></a>

## 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

### AASM 2019 recommendations for educational, behavioral, troubleshooting, and telemonitoring interventions

> “We recommend that educational interventions be given with initiation of PAP therapy in adults with OSA. (STRONG)”
> “We suggest that behavioral and/or troubleshooting interventions be given during the initial period of PAP therapy in adults with OSA. (CONDITIONAL)”
> “We suggest that clinicians use telemonitoring-guided interventions during the initial period of PAP therapy in adults with OSA. (CONDITIONAL)”
> “The TF identified 18 RCTs that evaluated the use of some combination of an educational, behavioral, or troubleshooting intervention as an adjunct to initiation of PAP therapy compared to PAP therapy with usual care. Meta-analyses demonstrated a clinically significant improvement in PAP adherence with all three types of interventions.”

Source: [Patil et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6374094/)

<a id="topic-2.2.2.4-2"></a>

### VA/DoD 2025 recommendation for in-person or telehealth adherence interventions

> “For treatment of obstructive sleep apnea in patients who are prescribed positive airway pressure therapy, we suggest the use of in-person or telehealth educational, behavioral, and supportive interventions to improve PAP usage. (Weak for | Reviewed, New-replaced)”
> “Behavioral interventions showed the most significance in hourly usage with an increase in average PAP usage per night by 1.31 hours per night (95% CI: 0.95 to 1.66) when compared to usual care.”
> “In a meta-analysis from Niu et al. (2023)(217) telemedicine-based follow-up significantly improved PAP use greater than 4 hours a night by 10.67% (95% CI: 4.97 to 16.37; p<0.001)”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.4-3"></a>

### VA/DoD 2025 recommendation for a short course of eszopiclone to improve positive airway pressure usage

> “For treatment of obstructive sleep apnea in appropriate patients, we suggest up to a two-week course of eszopiclone to improve positive airway pressure usage. (Weak for | Reviewed, New-added)”
> “The systematic review (SR) by Wang et al. (2021)(220) included six randomized controlled trials (RCTs) and two retrospective cohort studies, finding that eszopiclone significantly improved PAP usage compared to placebo or no treatment (Mean Difference: 0.83 hours/night; 95% CI: 0.70 to 0.96; P<0.00001).”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.4-4"></a>

### Behavioral intervention effect on CPAP use across studies

> “Behavioral intervention improved adherence rates by ~1 h per night on average.”

Source: [Rotenberg et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4992257/)

<a id="topic-2.2.2.4-5"></a>

### Multidisciplinary follow-up of hypoglossal nerve stimulation

> “Patients who use HGNS therapy require periodic evaluation to assess their nightly use of the device, the effectiveness of the therapy for improving their OSA symptoms, and adverse effects of therapy.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.4-6"></a>

### Manufacturer plans for telehealth pathways and durable medical equipment provider engagement

> “If Oxnimbi is approved, we plan to engage where possible with DME organizations to help identify patients who are unable to initiate or sustain PAP therapy and who may require further clinical evaluation by their healthcare providers.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
